摘要
目的:探讨中西医结合方案治疗慢性乙型肝炎(CHB)的临床疗效。方法:76例CHB患者随机分成观察组39例和对照组37例。对照组采用派罗欣180μg/次,1次/周,sc,观察组在此基础上根据不同中医证候加用十味溪黄草颗粒或人参健脾丸。疗程均为48周。观测两组肝功能、中医证候积分、HBV-DNA定量及乙肝病毒血清标志物。结果:疗后24,48周观察组血清HBV-DNA水平低于对照组(P<0.05,P<0.01);疗后12,24,48周观察组中医证候积分明显低于对照组(P<0.01);疗后24,48周观察组门冬氨酸氨基转移酶(AST),丙氨酸氨基转移酶(ALT),总胆红素(TBil)水平低于对照组(P<0.05,P<0.01);疗后48周观察组肝功复常率及HBV-DNA转阴率均优于对照组(P<0.05)。结论:中西医结合治疗CHB较单纯的西医治疗有更明显的临床优势,值得推广使用。
Objective： To Investigate the clinical effect on chronic viral hepatitis B （CHB） treated with integrative Chinese and western medicine. Method： Sixty cases of chronic viral hepatitis B were randomized into observation group （39 cases） and control group （37 cases）. The control group was treated with pegasys 180 μg/ times, 1time/week, subcutaneously; the observation group was treated with the Shiwei Xihuangcao granules or Renshen Jianpi wan according to the different traditional Chinese medicine （TCM） symptoms on the basis of the control group. The course of treatment was 48 weeks. Liver function, TCM syndrome score, HBV-DNA quantitative and HBV markers of two groups were observed. Result： The level of aspartate aminotransferase （AST） , alanine transaminase （ALT）, total bilirubin （TBil） of the observation group was lower than that of the control group after 24, 48 weeks treatment （P 〈 O. 05, P 〈 0.01 ）. The TCM syndrome score of the observation group was lower than the control group after 12, 24, 48 weeks treatment （P 〈 0.01 ）. The level of serum HBV-DNA of the obseivation group was lower than the control group after 24, 48 weeks treatment （P 〈 0.05, P 〈 0.01 ）. The Liver function normalization rate and HBV-DNA negative rate of the observation group were better than the control group after 48 weeks treatment （P 〈 0.05）. Conclusion ： Integrative treatment of CHB has more obvious clinical advantages than the simple treatment of western medicine and worth to promote to use clinically.
出处
《中国实验方剂学杂志》
CAS
北大核心
2012年第24期330-333,共4页
Chinese Journal of Experimental Traditional Medical Formulae
关键词
慢性乙型肝炎
派罗欣
十味溪黄草颗粒
人参健脾丸
临床疗效
chronic hepatitis B
pegasys
Shiwei Xihuangcao gnanules
Renshen Jianpi wan
clinical efficacy
